Liver Transplant Program

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The purpose of this multicenter, double-blind, randomized, placebo-controlled study is to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

2. A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

   Jacksonville, Fla.

   The purpose of this study is to evaluate the safety and effectiveness of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).

3. A Study to Evaluate the Safety and Effectiveness of BMS-986036 (PEG-FGF21) in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis

   Jacksonville, Fla.

   The purpose of this study is to confirm and extend the results observed in the Phase 1 and 2a studies with BMS-986036. Specifically, this study aims to demonstrate in participants with NASH and compensated cirrhosis, the effectiveness of BMS-986036 using histological and noninvasive endpoints, and the safety of BMS-986036 as assessed by AEs, lab results and bone mineral density (BMD) monitoring.

4. Validation of Cognitive Tests in Elderly Cirrhotic Patients

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to define the prevalence and impact of cognitive impairment and their impact on HRQOL in elderly patients with cirrhosis compared to elderly patients without cirrhosis.

5. A Study of Using Ultrasound to Evaluate Post-Transplant Acute Liver Rejection

   Rochester, Minn.

   Liver biopsy is routinely performed at day 7 after liver transplant at Mayo to evaluate acute liver rejection.The purpose of this study is to assess the feasibility of a non-invasive evaluation of acute liver rejection by using ultrasound measurements.

6. A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis

   Scottsdale/Phoenix, Ariz.

   This is a 5-year, longitudinal, observational study of patients with PBC designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.

7. A Study to Confirm the Effectiveness and Safety of Terlipressin for Treatment of Hepatorenal Syndrome Type 1

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to confirm the effectiveness and safety of  terlipressin in the treatment of adult patients with hepatorenal syndrome (HRS) type 1.

8. Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The primary objectives of this study are: - To assess the safety and tolerability of selonsertib (SEL), GS-0976, and GS-9674, administered alone or in combination, in participants with bridging fibrosis or compensated cirrhosis due to Nonalcoholic Steatohepatitis (NASH) - To evaluate changes in liver fibrosis, without worsening of NASH

9. Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   The primary objective of this study is to evaluate whether obeticholic acid (OCA; INT-747) can lead to histological improvement in fibrosis with no worsening of NASH in adults with compensated cirrhosis due to NASH.

10. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Fibrosis

    Scottsdale/Phoenix, Ariz.

    The purpose of this study is to evaluate the safety and effectiveness of BMS-986036 in adults with nonalcoholic steatophepatitis (NASH) and compensated liver fibrosis.